MedTrace Logo

Malaria Prevention Cambodia

NCT01624337 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 231

Last updated 2016-07-12

No results posted yet for this study

Summary

Trial of monthly DHA-piperaquine for malaria prevention in health volunteers.

Conditions

Interventions

DRUG

DHA-piperaquine

Drug: Dihydroartemisinin piperaquine 40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)

DRUG

placebo

Sponsors & Collaborators

  • National Centre for Parasitology, Entomology and Malaria Control, Cambodia

    collaborator OTHER

  • Royal Cambodian Armed Forces

    collaborator UNKNOWN

  • United States Army Medical Materiel Development Activity

    collaborator FED

  • Armed Forces Research Institute of Medical Sciences, Thailand

    lead OTHER_GOV

Principal Investigators

  • DAVID SAUNDERS, MD, MPH · Armed Forces Research Institute of Medical Sciences, Thailand

  • Chanthap Lon, MD · Armed Forces Research Institute of Medical Sciences, Thailand

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-08-31
Completion
2015-06-30

Countries

  • Cambodia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01624337 on ClinicalTrials.gov